Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
AOD-9604
GH fragment studied in human obesity trials for lipolytic effects via β-adrenergic pathways.
Tier Bmed-high risk
02· Subject
CJC-1295
Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.
Tier Bhigh risk
01 · At a glance
| Decision factor | AOD-9604 | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Primary fit | fat loss & metabolism research where you want a clear starting point | muscle growth & strength and fat loss & metabolism comparisons | fat loss & metabolism and gh axis optimization comparisons |
| Evidence | Tier B | Tier B | Tier A |
| Risk | med-high | high | low |
| Experience level | intermediate | intermediate | advanced |
| Budget tier | mid | mid | premium |
| Administration route | oral, subcutaneous | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | AOD-9604 | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Goal fit | Fat Loss & Metabolism | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | Fat Loss & Metabolism, GH Axis Optimization |
| What users compare it for | Modest lipolytic/fat loss signals in trials. Not equivalent to GLP-1 class. | Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes). | Visceral fat reduction in HIV lipodystrophy (evidence-backed). General weight loss claims are limited. |
| Onset timeline | Clinical trials measured outcomes over ~12 weeks; weight loss signals modest. | Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose. | Clinical endpoints assessed at 26 weeks in pivotal studies. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | AOD-9604 | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Adverse effects | Overall tolerability similar to placebo in safety reports; some serious AEs in dose groups (judged unrelated by investigators). | Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses. | Increased neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance/diabetes, hypersensitivity. |
| Contraindications | No formal label. | GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1. | Active malignancy, pregnancy, pituitary gland disorders (per label). |
| Interaction notes | Minimal established interactions. | Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose. | CYP450-metabolized drugs; glucocorticoid replacement requirements may be affected. |
| Regulatory status | Not approved | Not approved | Prescription-approved |
| FDA flag | FDA status unclear | FDA compounding caution | No current flag noted |
| WADA status | WADA S2 | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | AOD-9604 | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54 | No age guidance yet |
| Life-stage note | Not yet documented | Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited. | Not yet documented |
| Monitoring burden | Not specified | high | Not specified |
| Follow-up cadence | Not yet documented | Reassess at startup and then roughly every few months if continuing. | Not yet documented |
05 · Cost & sourcing
| Decision factor | AOD-9604 | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Typical cycle cost | €963.31 | $143.98 | $600.00 |
| Estimated monthly cost | €321.10 | $47.99 | $600.00 |
| Cost confidence | High confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | AOD-9604 | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Tracked vendor listings | 2 listings | 3 listings | 3 listings |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | At least one listing is a blend rather than a clean standalone product, so review the product page carefully. | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Better as a standalone decision |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.